1. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Issue 10246 (25th July 2020) Authors: Simpson, Eric L; Sinclair, Rodney; Forman, Seth; Wollenberg, Andreas; Aschoff, Roland; Cork, Michael; Bieber, Thomas; Thyssen, Jacob P; Yosipovitch, Gil; Flohr, Carsten; Magnolo, Nina; Maari, Catherine; Feeney, Claire; Biswas, Pinaki; Tatulych, Svitlana; Valdez, Hernan; Rojo, Ricardo Journal: Lancet Issue: Volume 396:Issue 10246(2020) Page Start: 255 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials. (1st June 2022) Authors: Yosipovitch, Gil; Papp, Kim; Forman, Seth; Han, George; Waibel, Jill; Rueda, Maria J.; Sun, Luna; Chen, Yun‐Fei; Goldblum, Orin; Pierce, Evangeline; Silverberg, Jonathan I. Journal: British journal of dermatology Issue: Volume 186:Number 6(2022) Page Start: 1047 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials. (21st April 2022) Authors: Yosipovitch, Gil; Papp, Kim; Forman, Seth; Han, George; Waibel, Jill; Rueda, Maria J.; Sun, Luna; Chen, Yun‐Fei; Goldblum, Orin; Pierce, Evangeline; Silverberg, Jonathan I. Journal: British journal of dermatology Issue: Volume 186:Number 6(2022) Page Start: 1047 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗